D

Zoetis Inc. ZTS

NYSE
Recommendation
Dividend Power Score
Day's Range
$82.15$86.58
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
My Lists My Alerts

Company Overview

Zoetis Inc. is a global animal health company focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision animal health technologies for livestock and companion animals. The company operates within the broader animal health and veterinary pharmaceuticals industry and serves veterinarians, livestock producers, pet owners, and animal health distributors. Revenue is primarily generated through the sale of animal medicines and vaccines across therapeutic categories including anti-infectives, parasiticides, dermatology, pain management, reproductive products, and diagnostic solutions.

Zoetis traces its origins to Pfizer’s animal health division, which operated for decades before being spun off through an initial public offering in 2013. Since becoming an independent public company, Zoetis has expanded through internal research and targeted acquisitions, strengthening its position in companion animal therapeutics and diagnostics. The company is widely recognized for its scale, broad product portfolio, established veterinary relationships, and diversified exposure across species and geographies. Its strategic positioning is supported by extensive research and development capabilities, global manufacturing infrastructure, and a strong portfolio of established brands in both livestock and pet care markets.

Business Operations

Zoetis organizes its operations primarily around products for companion animals and livestock species. Companion animal products include medicines, vaccines, diagnostics, and digital technologies for dogs, cats, and horses, while livestock offerings support cattle, swine, poultry, fish, and sheep producers. Key revenue drivers include parasiticides such as Simparica, dermatology products including Apoquel and Cytopoint, vaccines, anti-infectives, and diagnostic platforms obtained through acquisitions. The company distributes products through veterinary clinics, distributors, retailers, and agricultural channels in numerous international markets.

The company maintains operations across North America, Europe, Latin America, Asia Pacific, Africa, and the Middle East. Zoetis controls a substantial global manufacturing and research network, including biologics and pharmaceutical production facilities. Major subsidiaries and acquired businesses include Phoenix Lab, Abaxis, and Basepaws, which expanded Zoetis’ diagnostics and genetics capabilities. The company also collaborates with veterinary professionals, academic institutions, and agricultural stakeholders to support animal disease prevention, productivity, and companion animal care.

Strategic Position & Investments

Zoetis has emphasized growth in companion animal therapeutics, diagnostics, genetics, and precision animal health technologies. Strategic investment priorities include expanding recurring revenue streams from diagnostics, increasing lifecycle management of established medicines, and advancing biologic and monoclonal antibody therapies for pets. The company has invested significantly in dermatology, pain management, diagnostics integration, and digital veterinary tools to deepen customer engagement and strengthen veterinary clinic workflows.

Acquisitions have played a central role in Zoetis’ strategy. The acquisition of Abaxis materially expanded the company’s veterinary diagnostics platform, while investments in genetics and data-driven animal health technologies strengthened precision livestock management capabilities. Zoetis has also pursued innovation in monoclonal antibodies and vaccine technologies aimed at chronic conditions in companion animals. Public filings and investor communications indicate continued focus on emerging areas such as predictive diagnostics, genomic testing, and integrated veterinary care ecosystems.

Geographic Footprint

Zoetis is headquartered in Parsippany, New Jersey, and operates in more than 100 countries. The company maintains a particularly strong market presence in North America and Europe, while also expanding across Latin America, Asia-Pacific, the Middle East, and Africa. International operations contribute a substantial portion of annual revenue, reflecting broad demand for livestock productivity solutions and companion animal healthcare products globally.

The company’s manufacturing, research, and commercial infrastructure spans multiple continents, supporting localized distribution and regulatory compliance. Zoetis maintains research and production facilities in the United States, Belgium, Brazil, Australia, China, and other markets. Its international reach allows it to participate in both developed veterinary markets and higher-growth emerging agricultural economies, supporting diversified exposure across regional economic cycles and animal species.

Leadership & Governance

Zoetis is led by an executive team with backgrounds in pharmaceuticals, veterinary medicine, biotechnology, finance, and global operations. Since its separation from Pfizer, leadership has emphasized innovation-driven growth, portfolio diversification, operational discipline, and expansion of companion animal healthcare capabilities. The company’s governance structure follows public-company standards outlined in SEC filings and related corporate governance disclosures.

Key executives include:

  • Kristin Peck – Chief Executive Officer
  • Wetteny Joseph – Executive Vice President and Chief Financial Officer
  • Roxanne Lagano – Executive Vice President and Chief Human Resources Officer
  • Keith Sarbaugh – Executive Vice President and Chief Manufacturing and Supply Officer
  • Jamie Brannan – Executive Vice President and Chief Commercial Officer
  • Mahesh Kumar – Executive Vice President and President, Global Diagnostics
  • Shannon Kellogg – Executive Vice President and General Counsel

Leadership communications and investor materials consistently describe the company’s strategic vision as centered on advancing animal care through science, innovation, diagnostics integration, and global veterinary partnerships.

Data compiled by narrative technology. May contain errors.

Top Tech Stocks
See All »
B
AAPL NASDAQ $352.45
B
MSFT NASDAQ $508.29
B
NVDA NASDAQ $150.96
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $127.36
B
Top Financial Stocks
See All »
B
A
JPM NYSE $324.11
B
V NYSE $415.22
Top Energy Stocks
See All »
B
CVX NYSE $205.88
B
COP NYSE $134.40
Top Health Care Stocks
See All »
B
LLY NYSE $1,382.75
B
JNJ NYSE $272.70
B
ABBV NYSE $286.01
Top Real Estate Stocks
See All »
B
PLD NYSE $125.22